Yield10 Bioscience reports Q3 EPS (71c), consensus (65c)

Reports Q3 revenue $111,000, consensus $130,000. "The significant market opportunity represented by demand for low-carbon index feedstock oil for biofuels is driving our efforts to develop and commercialize Camelina as a new industrial crop," said Oliver Peoples, CEO of Yield10 Bioscience. "In the third quarter, our market development efforts focused on securing growers to plant our winter Camelina varieties at a scale of up to 160 acres. As the season progresses into harvest next year, we plan to work closely with growers to build confidence and experience with the crop. We have also ramped up commercial seed production to enable our market development activities to expand in 2023."